AstraZeneca plc (AZN)
| Market Cap | 204.13B |
| Revenue (ttm) | 41.49B |
| Net Income (ttm) | -1.06B |
| Shares Out | 3.16B |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | 18.59 |
| Dividend | $1.42 (2.19%) |
| Ex-Dividend Date | Feb 24, 2022 |
| Volume | 6,443,382 |
| Open | 63.33 |
| Previous Close | 63.32 |
| Day's Range | 63.15 - 64.79 |
| 52-Week Range | 53.63 - 71.70 |
| Beta | 0.12 |
| Analysts | Buy |
| Price Target | 69.44 (+7.6%) |
| Earnings Date | Apr 29, 2022 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere...
Financial Performance
In 2021, AstraZeneca's revenue was $37.42 billion, an increase of 40.58% compared to the previous year's $26.62 billion. Earnings were $112.00 million, a decrease of -96.50%.
Financial StatementsAnalyst Forecast
According to 39 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is 69.44, which is an increase of 7.59% from the latest price.
News
AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
5 Stocks to Buy for the Coming Recession
Each of these stocks to buy are low-beta stocks with attractive dividend yields to help endure a recession. The post 5 Stocks to Buy for the Coming Recession appeared first on InvestorPlace.
Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca
MUNICH--(BUSINESS WIRE)--Proteros biostructures GmbH (“Proteros”), an expert in integrated structure-based drug discovery, announces today an expansion of its collaboration with AstraZeneca (LSE/STO/Nas...
Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination ...
CHENGDU, China and SEATTLE and LONDON , May 13, 2022 /PRNewswire/ -- BAILI-BIOPHARMACEUTICAL CO., LTD. ("Baili") and its wholly owned subsidiary, SystImmune, Inc ("SystImmune"), announced today that it ...
Is This Vaccine Stock in Trouble -- or Ready for a Rebound?
Inovio may be at a turning point.
3 Top Biotech Stocks to Buy Right Now
These three pharma stocks each pay market-beating dividends to shareholders.
3 Nasdaq 100 Stocks to Buy Hand Over Fist in May
These fast-paced stocks are plain-as-day bargains.
ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates
AstraZeneca's (AZN) first-quarter results reflect a beat on both counts (revenues and earnings). AZN maintains its 2022 guidance.
AstraZeneca CEO: ‘each of our businesses grew a lot in Q1'
AstraZeneca plc (LON: AZN) on Friday said vaccine contracts helped its Q1 financial results. Moving forward, however, it expects COVID-related sales to sink by 21% to 25%.
We expect slight decline in China due to price pressures, AstraZeneca CEO says
Pascal Soriot discusses the company's performance in China and the prospect for future M&A.
AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook
AstraZeneca Plc's (NASDAQ: AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of $10.99 billion. The growth reflects the contribution of the Alexion medicines a...
AstraZeneca revenue surges $11.39 billion, but sees COVID vaccine sales decline
AstraZeneca PLC said Friday that it expects sales of its Covid-19 medicines, including its vaccine, to decline by a low-to-mid twenties percentage during the year, but reported higher revenue in the fir...
AstraZeneca beats Q1 estimates, keeps 2022 forecasts
(Reuters) -AstraZeneca on Friday beat first-quarter sales and profit expectations and stood by its forecasts for 2022 as newer therapies for kidney disease and rare conditions offset an expected decline...
Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN
Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.
Should You Buy AstraZeneca (AZN) Ahead of Earnings?
AstraZeneca (AZN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Low Metastatic Breast Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Low Metastatic Breast Cancer
Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, supporting the indication of a single priming dose ...
AstraZeneca's Tremelimumab/Imfinzi Combo Regime Goes Under Priority FDA Review For Liver Cancer
The FDA has accepted for review AstraZeneca Plc's (NASDAQ: AZN) marketing application for tremelimumab as a single priming dose added to Imfinzi (durvalumab) for unresectable hepatocellular carcinoma (H...
These Dividend Stocks Are Trouncing the Market -- Are They Still Buys?
Investors don't like these stocks only because of their dividends.
2 Dividend Stocks to Buy and Hold Forever
These two companies have been around a while.
2 Charts Big Pharma Investors Need to Understand
The industry's leaders will fight to maintain their ranking over the next few years.
AstraZeneca's (AZN) Enhertu sBLA Receives FDA Priority Tag
FDA grants priority review to AstraZeneca (AZN) and Daiichi Sankyo's sBLA seeking approval of Enhertu for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC).
ENHERTU® Granted Priority Review in the U.S. for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Ce...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have received notification of acceptance of the supplemental Biologics License Application ...
AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in Chi...
SHANGHAI, China, April 18, 2022 (GLOBE NEWSWIRE) -- Amoy Diagnostics Co., Ltd (AmoyDx), a China based innovative molecular diagnostics company (SZSE: 300685), today announces that it has entered into a ...